

(EE)

CLAIMS

1. A use of a nucleic acid-binding chemotherapeutic agent for the preparation of a pharmaceutical composition for the treatment of a disease caused by virions, wherein the nucleic acid-binding chemotherapeutic agent is capable of complexing a metal ion, yielding a complex that promotes the formation of hydroxyl radicals from hydrogen peroxide.

2. A use according to claim 1, characterized in that the nucleic acid-binding chemotherapeutic agent is selected from the group comprising bleomycin, adriamycin, and their derivatives.

3. A use according to claim 1 or 2, characterized in that the nucleic acid-binding chemotherapeutic agent is used for the preparation of a pharmaceutical composition for the treatment of a disease caused by an RNA virus.

4. A use according to claim 3, characterized in that the nucleic acid-binding chemotherapeutic agent is used for the preparation of a pharmaceutical composition for the treatment of a disease caused by a HIV.

5. A pharmaceutical combination composition comprising a nucleic acid-binding chemotherapeutic agent comprising a metal ion complexed therewith, which complex is able to promote the formation of hydroxyl radicals from hydrogen peroxide, together with a pharmaceutically acceptable carrier or excipient, and which also comprises an iron-chelating compound which binds iron in a form in which it is unable to promote the formation of hydroxyl radicals from hydrogen peroxide.

6. A pharmaceutical combination composition according to claim 5, characterized in that iron-chelating compound has an iron-chelating capacity which is preferably at least three times lower, more preferably at least ten times lower than that of the nucleic acid-binding chemotherapeutic agent.

add a1

AMENDED SHEET